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The aim is to evaluate the humanistic outcomes in type 2 diabetic patients by the adoption of pharmacotherapy 
follow-up in community pharmacies. Controlled, non-randomized, 12-months trial; n=161 patients 
distributed into control and intervention groups; 6 community pharmacies involved, all in the Curitiba city 
region, in the state of Paraná were used. The health-related quality of life (HRQoL) and the satisfaction 
index were determined using both the DQOL assessment tool, which measures HRQoL, and the satisfaction 
evaluation tool (QSSF). Interventions on 119 negative therapeutic outcomes were done (2.3/patient 
[SD=1.6]); the most commonly found problems were related to ineffectiveness of pharmacotherapy (68.1%). 
The Intervention-Group showed a significant improvement in HRQoL compared with the Control Group 
(0.08 vs -0.01, respectively; p=0.036). Satisfaction and impact domains presented the most significant 
improvement (0.13 vs 0.00 [p=0.030] and 0.07 vs -0.04 [p=0.033], respectively). After adjusting for 
baseline variables, the difference in improvement scores between groups on the QSSF was attributed to 
the allocation of patients in the intervention group. Pharmacotherapy follow-up of type 2 diabetic patients 
in community pharmacies can improve the HRQoL and satisfaction of patients.
Uniterms: Diabetes mellitus/type 2/pharmaceutical care. Pharmaceutical care. Community pharmacy. 
Pharmacists/community action.
O objetivo foi avaliar os resultados humanísticos de pacientes com diabetes tipo 2, por meio da adoção 
de acompanhamento farmacoterapêutico nas farmácias comunitárias. Utilizaram-se: ensaio controlado, 
não-randomizado, de 12 meses; n=161 pacientes, distribuídos entre Grupo Controle e de Intervenção, e 
6 farmácias comunitárias, todas na região da cidade de Curitiba, Estado do Paraná. A qualidade de vida 
relacionada à saúde (HRQoL) e o índice de satisfação foram determinados utilizando a ferramenta de 
avaliação DQOL, que mede a HRQoL, e a ferramenta de avaliação da satisfação (QSSF). Intervenções 
em 119 resultados terapêuticos foram efetuadas (2,3/paciente [SD=1,6]. Os problemas  mais comumente 
encontrados foram aqueles relacionados à ineficácia da farmacoterapia (68,1%). O Grupo de Intervenção 
mostrou melhoria significativa da HRQoL  em comparação ao Grupo Controle (0,08 versus 0,00 [p=0,030 
e 0,07 versus -0,04 [p=0,033], respectivamente). Após o ajuste da linha base das variáveis, a diferença 
na contagem de melhoramento entre os grupos no QSSF foi atribuída à alocação de pacientes no Grupo 
de Intervenção. O acompanhamento farmacoterapêutico em pacientes de diabetes tipo 2 em farmácias 
comunitárias pode melhorar a HRQoL e a satisfação dos pacientes.
Unitermos: Diabetes melito/tipo 2/atenção farmacêutica. Atenção farmacêutica. Farmácia comunitária. 
Farmacêuticos/ação comunitária.
INTRODUCTION
Pharmaceutical care is a professional practice 
recommended by the WHO and other national and inter-
national entities (De Castro et al., 2006). It contributes to 
the resolution of medical conditions and can help avoid 
undesirable outcomes in relation to patients’ drug therapy 
problems (DTP) (Hepler and Strand, 1990; Organización 
Mundial De La Salud, 1993), resulting in benefits to pa-
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tients and to society. Humanistic outcomes, also known 
as patients’ reported outcomes, involve the effect of tre-
atment and pathology on the patient´s functional status, 
quality of life and satisfaction with the particulars of their 
care (Kozma,1993; McCaffrey, 2000). Evaluation of hu-
manistic outcomes, often little valued by professionals, 
is important, along with clinical outcomes, especially in 
chronic diseases such as Diabetes Mellitus (DM) (DCCT 
Group, 1988).
Of the different types of diabetes, DM type 2 is the 
most prevalent worldwide, accounting for 90 to 95% of 
all cases of diabetes. Patients with this type of diabetes are 
usually overweight or obese, and tend to be diagnosed after 
40 years of age (Sociedade Brasileira de Diabetes, 2007). 
By the year 2010, the worldwide prevalence of people with 
diabetes is set to rise to an estmated221 million people and 
by 2030, 300 million (Sociedade Brasileira de Diabetes, 
2007; Zimmet et al., 2001).
Due to its high prevalence, chronic nature and the 
severity of its complications, this disease represents a 
high cost to society. This cost is not only economic, but 
also involves intangible aspects such as pain, anxiety and 
decreased quality of life of those afflicted (Sociedade 
Brasileira de Diabetes, 2005, 2007). The quality of life of 
diabetic patients is influenced by several factors, among 
which are the presence of complications and type of treat-
ment used (Mata Cases et al., 2003; Redekop et al., 2002)
Another form of assessment of humanistic outco-
mes and thus of the quality of interventions is the extent 
of patient satisfaction with the pharmaceutical care they 
receive. Satisfaction is a subjective parameter which re-
flects the preferences and expectations of patients with the 
service provided, especially in technical and interpersonal 
aspects, thus allowing assessment of health professionals’ 
performance (Larson et al., 2002).
In this study, humanistic outcomes for patients with 
diabetes type 2 were evaluated from the perspective of 
provision of pharmaceutical care over 12 months. 
PATIENTS AND METHODS
General study characteristics
A longitudinal, controlled, non-randomized study 
was conducted, comparing results of 161 subjects with 
type 2 DM distributed in two groups: one group received 
pharmacotherapeutic follow-up (PTF) in community phar-
macies (intervention group), to a level above the normal 
standard of care, and the other received only standard care 
by the health team (control group).
The study was conducted between June 2004 and 
March 2006 (21 months), and four community pharmacies 
located in Curitiba (PR) (2 pharmacies), Colombo (PR) (1 
pharmacy) and Paranaguá (PR) (1 pharmacy) participated 
in the intervention group. All of these pharmacies had 
appropriate structure for the project, and their pharmacists 
received training in pharmacotherapeutic follow-up using 
the Dader Method (Machuca et al., 2003).
The control group was composed of patients with 
type 2 DM who did not receive Pharmacotherapeutic 
follow-up, were allocated to a Primary Care Unit (Nei-
ghborhood Cajuru – Curitiba - PR) and a community 
pharmacy located in Campo Largo (neighboring Curitiba), 
in which the pharmacists did not apply PTF. The stan-
dard service offered to control patients consisted of the 
following exams: laboratory blood examinations, blood 
pressure measurement (BP), body weight, and measure-
ment of abdominal circumference (AC). The results were 
delivered to the patients and to their doctors who ordered 
the tests. In addition, pharmacists and technicians had 
dispensing medications in control pharmacies as is usual, 
and guidance on correct use of drugs.
Eligible patients were 30 years of age or older and 
were diagnosed with type 2 DM, with a prescription for 
hypoglycemic agents and/or insulin. Patients who were 
bedridden or unable to go to the pharmacy during the mo-
nitoring period were considered ineligible for the study. 
In the control group, withdrawals were considered to be 
patients who did not undergo at least 2 parameter measure 
sessions (baseline and end of study). In the intervention 
group, patients who remained for more than 3 consecuti-
ve months without pharmaceutical care during the study 
period were considered to be withdrawals from the study. 
These patients were excluded from the final evaluation.
Variables and measuring instruments
The humanistic outcomes considered were quality of 
life and satisfaction with the pharmacy services. Quality 
of life was measured by the evaluation instrument DQOL-
Brazil, validated in Portuguese. The instrument consists of 
44 multiple-choice questions organized into four domains: 
Satisfaction - 15 questions, Impact - 20 questions, Vocatio-
nal / social preoccupations - 7 questions, diabetes related 
concerns - 4 issues (Correr et al., 2008th; DCCT Group, 
1988). The instrument’s scale of measurement is Likert 
type, numbered from 1 to 5 according to the intensity of 
satisfaction (1 - very satisfied, 2 – quite satisfied, 3 – mo-
derately satisfied, 4 - somewhat satisfied, 5 - unsatisfied); 
or frequency (1 - never, 2 - almost never, 3 - sometimes, 
4 - often, 5 - always) (DCCT Group, 1988). The scale used 
in the original instrument was converted to a scale from 
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0.00 to 1.00, where 0.00 represents the worst perception 
of quality of life and 1.00 the best possible outcome for 
quality of life (Correr et al., 2008a).
The patients’ satisfaction data were obtained using 
the satisfaction with the pharmacy services questionnaire, 
also validated for the Portuguese language from the origi-
nal instrument Pharmacy Services Questionnaire, develo-
ped by Larson, Rovers et al. (Correr et al., 2008b; Larson 
et al., 2002). In addition to the original questionnaire in 
English, there is also a version translated into Portuguese 
from Portugal (Iglésias et al., 2005).
The questionnaire poses 20 direct questions, grou-
ped into two domains: Friendly Explanation, with 11 items 
related to dispensing services and structural aspects of the 
dispensing pharmacy, and to Drug Therapy Management, 
with 9 items regarding services provided by the pharmacist 
related to the patient’s treatment. The patients answered 
each question on a Likert 5-point scale, which included 
the options: excellent, very good, good, moderate and poor 
(Correr et al., 2008b). The overall score for each patient 
was measured by the mean of 20 responses, where results 
closer to 5 indicate greater satisfaction.
Description of intervention
Each patient was monitored individually for a 
12-month period. In the intervention group, the pharma-
cist employed a Pharmacotherapeutic follow-up protocol, 
developed by Grupo de Investigación en Atención Far-
macéutica, from the University of Granada (Spain). This 
protocol, called the Dáder method, has been in use since 
1999, appearing in several published studies (Armando et 
al., 2005; Cubero-Caballero et al., 2006; Fontana Raspanti 
and Sola Uthurry, 2003; Martínez-Romero et al., 2001; Sil-
va Castro et al., 2004). The process of patient monitoring 
applied by the participating pharmacists consisted of the 
following steps: 1) patient recruitment, 2) initial clinical 
interview, 3) situational analysis (detection of DTPs and 
their causes), 4) plan of pharmaceutical care and interven-
tions and 5) evaluation of results.
Recruitment onto the study was done while dis-
pensing hypoglycemic drugs and included those patients 
who sought out the pharmacist directly, in response to 
information obtained from posters announcing the study. 
For patients meeting the selection criteria and who agreed 
to participate, an initial interview was scheduled. Patients 
were instructed to bring along the medications they were 
currently taking, most recent prescriptions and laboratory 
exam results. After giving written informed consent, the 
initial step of data collection ensued, entailing patients 
being asked whether they would complete two additional 
questionnaires (quality of life and satisfaction with phar-
macy services).
The pharmacist collected information on socio-
demographic profiles, current health problems and medi-
cal history, medications in use (continuous and sporadic) 
and living habits. Pharmacological history was obtained, 
with specific emphasis on the patient’s use of drugs and 
adherence to therapy.
Based on the information from the initial inter-
view, the pharmacist, organized the data for analysis in 
a form called Situational Status, to identify ongoing or 
potential DTPs. The situational analysis considered all 
the medications used by each patient (related to diabetes 
or otherwise), as well as other continuous, occasional and 
self administrated medication. The clinical and laboratory 
results required were: fasting glycemia (FG), glycated 
hemoglobin (HbA1), blood pressure (BP), abdominal 
circumference (AC), Body Mass Index (BMI) and exams 
or other information brought by the patient.
Following the situational analysis, the pharmacist 
devised a care plan for each patient based on their indi-
vidual needs, information on how to use medications, 
referrals to medical or other services, advice on changes 
in lifestyle, guidance on food, education about the disease, 
and strategies for improving adherence to pharmacothera-
py. This plan was discussed with each patient, aiming to 
establish a relationship of mutual collaboration.
Each pharmaceutical intervention was recorded on 
a standardized form, and during the subsequent return of 
the patients, its evolution/response was evaluated.
Ethical and statistical analysis
The null hypothesis of this study was that there was 
no difference between changes in quality of life indicators 
and satisfaction between the groups. All data collected for 
the two groups of patients were entered into the database 
and tested for normal distribution by the Kolmogorov-
Smirnov test, before selection of the statistical tests. 
The mean and standard deviation (SD), 95% confidence 
interval (95% CI) were calculated. The mean and range 
intervals were used to describe results of HbA1, number 
of drugs in use, number of visits and time spent in con-
sultations.
For comparison of means between groups, Student’s 
t test or the Mann-Whitney test was used (depending on 
the distribution), and for proportions, Chi-square test or 
Fisher’s exact test (depending on the number of occur-
rences in the individual cells in each table). For analysis 
of correlations between data Pearson’s coefficient or 
Spearman’s was used. The ANOVA test was employed for 
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comparison between three or more means. In the analyses 
comparing outcomes between intervention and control 
groups the differences (delta) between baselines and 
observed results at the study end-point were considered.
To correct any differences in baseline characteris-
tics of groups of populations which could influence the 
outcomes, multivariate linear regression analyses were 
conducted. The results were adjusted for gender, age and 
time of diabetes diagnosis.
The organization of the database and statistical 
analysis was performed using the programs Microsoft 
Excel® 2003 and SPSS ® 12.0 for Windows. A probability 
of type I error of 5% was considered acceptable and a value 
of p <0.05 was considered significant.
This study was designed in accordance with the 
guidelines and regulatory standards for research invol-
ving humans and was approved by the Research Ethics 
Committee of the University Hospital from Federal 
University of Paraná in August 2003. All patients were 
informed about the research objectives and those who met 
the criteria for selection and agreed to participate signed 
the written informed consent.
RESULTS
Patient profiles
A total of 161 patients were included in the study, 
96 of whom completed the 12-month Pharmacothera-
peutic follow-up. The demographic and clinical data of 
the groups are presented in Table I. The groups matched 
for most parameters, except the Charlson index of co-
morbidity, access to health services and baseline values 
of HbA1 and BP.
Pharmaceutical service and interventions
In the intervention group, 574 patient visits to phar-
macies were recorded (n = 50) during the study period. 
These meetings between pharmacist and patient totaled 
174.5 hours of direct work, with an average of 4.2 hours 
per patient. There were 11.4 visits per patient (SD = 4.3), 
with an average time of 19.3 minutes for each service 
(SD = 6.6).
In the study group, 119 pharmaceutical interven-
tions were documented during the study period, with an 
average of 2.3 interventions per patient (SD = 1.6, 0-9). 
For 4 patients (8%) the intervention was not performed but 
the majority (40%) received 2 pharmaceutical interven-
tions during the follow-up. Considering only the diabetes 
treatment, 1.5 interventions per patient (SD = 1.1, 0-5) 
occurred on average. This corresponded to 63.9% of total 
interventions. Considering the number of interventions 
per patient, the rate of interventions related to diabetes 
was 72.3%.
There were diverse interventions, although the main 
targets of the interventions were to improve the patient’s 
adherence to drug treatment (27.7%) and change in dose(s) 
of product(s) (17.6%). Pharmaceutical interventions were 
accepted in 76.5% of cases. For patients referred to the 
doctor, in 68% of cases the medical conduct was in-line 
with the suggestions made by pharmacists to the patient, 
written or verbally. The medical treatment remained un-
changed in 11.8% of cases referred from the pharmacy.
Changes in quality of life
The initial and final HQoL scores were collected 
from 65 patients (67.7% of patients from each group). 
For the other patients, pharmacists could not apply the 
questionnaire at beginning and end of the research, due to 
the accumulation of activities related to Pharmacothera-
peutic follow-up or due to blank questions that precluded 
a reliable comparative analysis. Table II contains the 
baseline quality of life and domains that composed the 
questionnaire, and the observed changes in these indexes 
after 12 months of study.
There were no significant differences between the 
two groups in baseline values of DQOL, for their overall 
score or each of the four domains. After 12 months, all 
HQoL indexes in the intervention group showed improve-
ment. In the control group, on average, they remained un-
changed or poorer. Significant differences were observed 
in the overall score DQOL score (0.08 95% CI 0.0 to 0.16 
vs -0.01 95% CI -0.07 to 0.04, p = 0036) and in satisfaction 
and impact categories (Table II). In percentage terms, the 
intervention group had an improvement in quality of life 
of 8.6%, while in the control group there was a decrease 
of 1.6%.
Adjusting the baseline data for gender, age and 
time of diabetes diagnosis, the allocation of patients in 
the group that received Pharmacotherapeutic follow-up 
remains a significant predictor for changes in the ove-
rall quality of life score (regression coefficient = 0.248, 
p = 0.047). The same is true for domain satisfaction 
(regression coefficient = 0.250, p = 0.044) and impact 
(regression coefficient = 0.259, p = 0.040) but not in the 
social / vocational (p = 0.686) and concerns related to 
diabetes (p = 0.365) domains.
There were no differences between men and women 
in changes in the overall score for quality of life, or in each 
of their fields in both intervention and control groups sepa-
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rately, as in all the patients. The age group above 60 years 
was not important for the observed quality of life changes 
(regression coefficient = -0.138, p = 0.653).
Changes in satisfaction with pharmacy services
The initial and final scores for patient satisfaction 
with the pharmacy were collected for 70 patients (72.9% of 
total patients) and the results showed baseline differences 
between the two groups. Satisfaction was higher in the 
intervention group than in the Control Group (p = 0.022). 
In intervention Group (n = 35), the mean was 3.9 (SD = 1.0) 
and in the Control Group (n = 35) was 3.3 (SD = 1.0). After 
12 months, the biggest difference was observed in the group 
that received Pharmacotherapeutic follow-up (0.5 95% 
CI 0.1 to 0.9 vs. 0.2 95% CI -0.1 to 0.5); however, this 
difference was not significant (p = 0.120). Analyzing the 
domains, the baseline values differed between the groups 
in the managed therapy (p = 0.011) and in friendly exposure 
after 12 months, using the top score increase found in the 
intervention group (p = 0.043).
Given the baseline differences, baseline adjustments 
were made through a multivariate regression model of 
variables: gender, age, time of diagnosis of diabetes, and 
baseline score of satisfaction. Following this analysis, the 
allocation of patients into the intervention group emerges 
as the only positive predictor for the observed changes 
in overall satisfaction (regression coefficient = -0.348, 
TABLE I - Comparative analysis of baseline values between patients in the intervention and control groups who completed the 
study (n = 96)
Parameter†
Control Group
n=46
Intervention Group
n=50
p*
Gender n(%) Male 23 (50) 22 (44.0) 0.556
Female 23 (50) 28 (56.0)
Mean age (SD)  59.5 (11.0)  58.1 (10.3) 0.534
Diagnosis time mean (SD) 9.4 (7.8) 8.4 (8.7) 0.529
Charlson index of co-morbidity
mean (SD)
4.2 (1.4) 3.3 (1.2)  0.001‡
Access to health service n(%) Public 39 (84.8) 23 (46.0) <0.001‡
Private 3 (6.5) 11 (22.0)
Both 4 (8.7) 16 (32.0)
Schooling
n (%)
Primary incomplete 26 (56.5) 21 (42.0) 0.382
Primary complete 8 (17.4) 14 (28.0)
Secondary incomplete 1 (2.2) 5 (10.0)
Secondary completo 7 (15.2) 6 (12.0)
Higher incomplete 2 (4.3) 1 (2.0)
Higher complete 2 (4.3) 3 (6.0)
Participation in a diabetic group n (%) 7 (15.2) 12 (24.0) 0.281
Last medical consultation <6 months n(%) 40 (86.9) 41 (82.0) 0.339
HbA1 % (SD) 8.6 (1.0) 9.8 (2.0) <0.001‡
FG mg/dl(SD) 161.2 (53.2) 166.9 (56.4) 0.614
Systolic BP mmHg (SD) 147.7 (31.5) 134.9 (17.8)  0.016‡
Diastolic BP mmHg (SD) 91.1 (17.2) 81.5 (12.1)  0.002‡
BMI Kg/m2 (SD) 27.6 (4.4) 29.2 (4.9) 0.100
Male AC cm (SD)  96.2 (11.7) 97.1 (11.0) 0.778
Female AC cm (SD) 93.7 (8.5) 93.8 (11.7) 0.965
†Baseline data collected at study commencement. *Chi-square for two or more proportions and Student’s t to compare the means 
between independent groups. ‡Significant differences (p<0.05). 
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p = 0.001), in friendly exposure (regression coefficient = 
-0.381, p = 0.01) and in therapy management (regression 
coefficient = -0.301, p = 0.002).
There was no significant difference in initial values 
of satisfaction among adults and elderly (≥ 60 years) or 
changes in the overall score and domains after 12 months 
(p> 0.05). There were no differences in initial values of 
satisfaction between men and women (n = 70), although 
after 12 months, women had greater increases in overall 
satisfaction than men (0.6 ± 1.0 vs 0.1 ± 0.9, p = 0.04), 
particularly in the domain of therapy management 
(0.7 ± 1.0 vs 0.1 ± 1.0, p = 0.024).
DISCUSSION
The quality of life of patients with T2DM is ham-
pered not only by the consequences generated by the pa-
thology, but also by the DTPs themselves. In addition to 
the inconvenience created by pharmacotherapy, the need 
for implementation of injections or the use of high-cost 
medicines can also cause hardships. This study shows 
that the majority of diabetic patients suffer from DTPs, 
and that the majority of DTPs are related to the specific 
pharmacotherapy for T2DM. The vast majority of inter-
ventions, resulting in changes in patient treatment, were 
accepted by physicians. Of the total assistance given by 
the pharmacists, approximately one third was unrelated to 
the diabetic treatment.
The number of pharmaceutical interventions perfor-
med showed positive correlation with the total number of 
visits made (r = 0.363, p = 0.01). Whereas the interventions 
were performed before the occurrence of DTP, these data 
indicate that there is an increase in the probability of DTP 
detection as the amount of care increases.
The values assigned to HRQoL in each of the DQOL 
domains before the beginning of the PTF, showed no sta-
tistically significant difference between the two groups. 
Largest baseline values were observed in domains of social 
TABLE II - Changes observed in the quality of life indices of patients in the intervention and control groups after 12 months of 
study (n = 65)
Outcome Intervention Group (n=32) Control Group (n=33) p (baseline) p (change)
Baseline* Changes after 
12 months**
Baseline* Changes after 
12 months**
General DQOL 0.65 (0.13) 0.08 (0.00 to 0.16) 0.71 (0.14) -0.01 (-0.07 to 0.04) 0.160 0.036‡
Satisfaction domain 0.51 (0.14) 0.13 (0.05 to 0.21) 0.61 (0.21) 0.00 (-0.07 to 0.08) 0.071 0.030‡
Impact domain 0.66 (0.17) 0.07 (-0.01 to 0.15) 0.73 (0.17) -0.04 (-0.11 to 0.02) 0.312 0.033‡
Social and vocational 
concerns domain
0.87 (0.18) 0.03 (-0.05 to 0.11) 0.88 (0.19) 0.00 (-0.08 to 0.08) 0.977 0.628
Diabetes related concerns 
domain
0.71 (0.17) 0.06 (-0.03 to 0.16 0.76 (0.17) -0.00 (-0.10 to 0.10) 0.566 0.320
*Baseline data for clinical outcomes presented in mean (standard deviation); **Changes data observed after 12 months expressed 
in mean (confidence interval 95%); ‡ Significant differences (p<0.05); DQOL, Quality of life dictionary for diabetes (version 
validated for Brazil). The Likert scale (1 to 5) used in the original instrument (DCCT Group, 1988) was converted to a scale from 
0.00 to 1.00, where 0.00 corresponds to the worst quality of life perception and 1.00 to the best result for quality of life.
TABLE III - Changes observed in the rates of satisfaction with pharmacy services for patients in the Intervention and Control Groups 
after 12 months of study (n = 70)
Outcome Intervention Group (n=35) Control Group (n=35) p (baseline) p (changes)
Baseline* Changes after 
12 months**
Baseline* Changes after 
12 months**
General satisfaction 3.9 (1.0) 0.5 (0.2 - 0.9) 3.3 (1.0) 0.2 (-0.1 - 0.5) 0.022‡ 0.120
Friendly exposure domain 3.9 (0.9) 0.5 (0.2 - 0.8) 3.6 (0.9) 0.1 (-0.2 - 0.4) 0.120 0.043‡
Therapy management domain 3.8 (1.1) 0.6 (0.2 - 1.0) 3.1 (1.2) 0.3 (-0.1 - 0.6) 0.011‡ 0.254
*Baseline data for clinical outcomes presented as mean (standard deviation); ** Changes data observed after 12 months presented 
as mean (confidence interval 95%); ‡ Significant difference (p<0.05)
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and vocational concerns and worries related to diabetes. 
This indicates a better perception of quality of life in the-
se domains, compared to the treatment satisfaction and 
disease impact. The biggest difference between the initial 
groups emerged in the satisfaction domain, in that patients 
in the control group showed indices closer to 1.0, although 
this did not reach significance (p = 0.071).
The data show that PTF conducted by the pharma-
cists in community pharmacies led to an absolute increase 
in HRQL across all domains of the DQOL (satisfaction, 
impact, vocational and social concerns and preoccupations 
related to diabetes), whereas the satisfaction domain was 
the one which had the most evident improvement after 12 
months. This improvement was not statistically significant 
for social and vocational domains or concerns related to 
the DM for both groups. In general, the increase in HRQL 
did not occur in the group not receiving the extra services 
in pharmaceutical care. The index for most domains in the 
standard care group remained unchanged or decreased, 
indicating stability or worsening of quality of life.
As regards patients’ satisfaction with pharmacy ser-
vices, the baseline values were different for both groups 
(control and intervention) in overall score and the therapy 
management domain. This may be related to the influence 
of patients’ entry into the research study group and their 
levels of satisfaction in relation to the Control Group. After 
12 months, there was a greater improvement in patients’ 
satisfaction in the Intervention Group than in the Control 
Group, but this was statistically significant only for the 
friendly exposure domain. This lack of response could 
have resulted from adjustments in data and correction 
of baseline differences. Pharmacotherapeutic Follow-
up was a factor that impacted positively on the patients’ 
satisfaction, based on comparisons between Intervention 
and Control Groups.
This study showed similar results to previous studies 
conducted in other countries which evaluated the outcome 
of pharmaceutical care for various pathologies. The study 
by Elnour et al., assessed whether the introduction of the 
program of pharmaceutical care helped in improving 
HRQOL, among other outcomes. In their study, the SF-36 
was applied to measure the quality of life and all domains 
presented more significant improvement in the Interven-
tion Group (Elnour et al., 2008). Another study evaluated 
the effect of pharmaceutical care on humanistic outcomes 
of patients with heart failure and revealed similar findings: 
after 12 months of intervention, the HRQOL increased 
compared to the Control Group (Cabezas et al., 2006). 
Other studies in Brazil have found similar results working 
with one group of patients in analysis before and after 
intervention (Lyra et al., 2007; Lyra Junior et al., 2004).
Limitations
Among the several limitations of this study the main 
bias was the lack of randomization of patients between 
groups. The decision to work with intervention pharmacies 
and control pharmacies was made for three main reasons: 
(1) the operational difficulty of applying a different care 
process between patients within the same establishment 
in a non blinded study ; (2) problems recruiting patients 
who agreed to receive the standard care, knowing that 
other patients are receiving pharmaceutical care from 
other pharmacists; and (3) the ethical implications that 
would be imposed the pharmacist regarding decisions 
not to intervene in the treatment of patients allocated in 
the Control Group. The choice of intervention and control 
pharmacies allowed us to distinguish the type of services 
to patients, since in control pharmacies any type of phar-
macotherapeutic follow-up service was implemented 
during the study period. To minimize the influence of 
non-randomization on the results of the study, patients’ 
baseline characteristics were adjusted in comprehensive 
multiple linear regression models.
The completion of clinical studies in a community 
pharmacy environment poses many challenges. The first 
and perhaps most important characteristic is the essentially 
commercial nature of the pharmacies that differentiates 
them from units pertaining to health services. Neverthe-
less, the provision of a new service (pharmacotherapeutic 
follow-up) during recruitment presented no resistance 
among patients and it was relatively easy to achieve the 
goal originally established for 160 patients. In fact, at the 
end of recruitment period, further patients were interested 
in participating but could not be accommodated, due to the 
limitations of the project schedule and resources.
The most common reasons reported by patients 
who dropped out of the study were improvement in their 
laboratory exam results, lack of time or transportation 
difficulties attending appointments, lack of financial in-
centive from the project, or simply loss of interest in the 
service (in both groups). The main reason perceived by 
the researchers was that, after several months of follow-
up, those patients with improvement in glycemic and 
pressure control, lost interest in continuing attending 
the appointments, since these patients had to go to the 
pharmacy only to monitor and meet the objective of the 
research protocol. Furthermore, considering that the 
study was conducted in an actual practicing service, the 
rate of dropouts can be considered acceptable, because 
after 1 year, 52.6% of the patients were still being seen 
regularly in the Intervention Group.
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CONCLUSION
The adoption of a pharmaceutical care service in 
community pharmacies, focused on pharmacotherapeu-
tic follow-up and detection and resolution of problems 
associated with pharmacotherapy, is effective in im-
proving quality of life related to health and satisfaction 
with pharmacy services in patients with type 2 diabetes 
mellitus. These results should be evaluated in conjunction 
with clinical outcomes, and indicate the potential of this 
practice in patient care by the health team. Future studies 
can confirm these results in other groups of patients and 
different practice environments.
REFERENCES
ARMANDO, P.; SEMERIA, N.; TENLLADON, M.; SOLA, N. 
Pharmacotherapeutic follow-up of patients in community 
pharmacies. Atencion Primaria, v.36, n.3, p.129-134, 2005.
CABEZAS, C. L.; SALVADOR, C. F.; QUADRADA, D. 
C.; BARTÉS, A. A.; BORÉ, M. Y.; PEREAE, N. M.; 
PEIPOCH, H. Randomized clinical trial of a postdischarge 
pharmaceutical care program vs. regular follow-up in 
patients with heart failure. Farm. Hosp., v.30, n.6, p.328-
342. 2006.
CORRER, C. J.; PONTAROLO, R.; MELCHIORS, A. 
C.; ROSSIGNOLI, P.; FERNANDEZ-LLIMOSR, F.; 
RADOMINSKI, B. Translation to portuguese and validation 
of the Diabetes Quality Of Life Measure (DQOL-Brazil). 
Arq. Bras. Endocrinol. Metabol., v.52, n.3, p.515-522. 
2008a. (tirar a informação a da data)
CORRER, C. J.; PONTAROLO, R.; MELCHIORS, A. C.; 
SOUZA, R. A. P.; ROSSIGNOLIF, P.; FERNÁNDEZ-
LLIMÓS, F. Satisfação dos Usuários com serviços da 
farmácia: tradução e validação do Pharmacy Services 
Questionnaire para o Brasil”. Cad. Saúde Pública, v.25, 
n.1, p.87-96, 2009 
CUBERO-CABALLERO, S.; TORRES, M.; CAMPOS-
PEREZ, M. A.; GOMEZ DEL RIOM, S.; CALLEJA-
HERNANDEZ, A. Drug-related problems in the emergency 
department observation area of a third-level hospital. Farm. 
Hosp., v.30, n.3, p.187-192. 2006.
DCCT GROUP. Reliability and validity of a diabetes quality-
of-life measure for the diabetes control and complications 
trial (DCCT). The DCCT Research Group. Diabetes Care, 
v.11, n.9, p.725-732. 1988.
DE CASTRO, M. S.; CHEMELLO, C.; PILGER, D.; JUNGES, 
F.; BOHNEN, L.; ZIMMERMAN, L. M.; PAULINO, M. 
A.; JACOBS, U.; FERREIRAF, M. B. C.; FUCHS, D. 
Contribuição da atenção farmacêutica no tratamento de 
pacientes hipertensos. Rev. Bras. Hip., v.13, n.3, p.198-
202. 2006.
ELNOUR, A. A.; EL MUGAMMAR, I. T.; JABER, T.; 
REVELJ, T.; MCELNAY, C. Pharmaceutical care of 
patients with gestational diabetes mellitus. J. Eval. Clin. 
Pract., v.14, p.131-140. 2008.
FONTANA RASPANTI,  D. ;  SÓLA UTHURRY, N. . 
Pharmacotherapeutic follow-up in hospitalised paediatric 
patients: adapting Dáder methodology. Farm. Hosp., v.27, 
n.2, p.78-83. 2003.
HEPLER, C. D. STRAND, L. M. Opportunit ies and 
responsibilities in the pharmaceutical care. Am. J. Hosp. 
Pharm., v.47, n.3, p.533-543. 1990.
IGLÉSIAS, P.; SANTOS, H. S.; FERNÁNDEZ-LLIMÓS, F.; 
FONTES, E.; LEALC. MONTEIRO, M. Translation and 
Validation of the “Pharmacy Services Questionnaire” to 
Portuguese (european). Seg. Farmacoter., v.3, n.1, p.43-
56, 2005.
KOZMA, C. M. Economic, Clinical, and Humanistic Outcomes: 
A Planning Model for Pharmacoeconomic Research. Clin. 
Ther., n.15, p.1121-1132, 1993.
LARSON, L. N.; ROVERSL, J. P.; MACKEIGAN, D. Patient 
satisfaction with pharmaceutical care: update of a validated 
instrument. J. Am. Pharm. Assoc. (Wash), v.42, n.1, p.44-
50, 2002.
LYRA JR., D. P.; KHEIR, N.; ROCHA, C. E.; ABRIATA, J. P.; 
SANTOSI, C. B. D.; PELA, R. Impact of pharmaceutical 
care interventions in the identification and resolution of 
drug-related problems and on quality of life in a group of 
elderly outpatients in Ribeirão Preto (SP), Brazil. Ther. Clin. 
Risk Manag., v.3, n.6, p.989-998, 2007.
LYRA JR., D.; AMARAL, R. T.; ABRIATAI, J. P.; PELÁ, 
R. Satisfaction as an outcome of a pharmaceutical care 
program for elderly in Ribeirão Preto – São Paulo (Brazil). 
Seguim. Farmacoter., v.3, n.30, p.30-42, 2004.
MACHUCA, M.; FERNÁNDEZ-LLIMÓSM, F.; FAUS, J. 
Método Dáder: guía de seguimiento farmacoterapêutico. 
Granada: Universidade de Granada, 2003. 47 p.
Effect of a Pharmaceutical Care Program on quality of life and satisfaction with pharmacy services 817
MARTÍNEZ-ROMERO, F.; FERNÁNDEZ-LLIMÓS, F.; 
GASTELURRUTIA, M. A.; PARRASM, M.; FAUS, J. 
Pilot phase results of the Dáder programme for drug therapy 
follow up. Ars Pharm., v.42, n.1, p.53-65, 2001.
MATA CASES, M.; ROSET GAMISANS, M.; BADIA LLACH, 
X.; ANTONANZAS VILLARJ, F.; RAGEL ALCAZAR, 
J. Effect of type-2 diabetes mellitus on the quality of life 
of patients treated at primary care consultations in Spain. 
Atencion Primaria, v.31, n.8, p.493-499. 2003.
McCAFFREY III, D.J. Patient satisfaction: the forgotten 
outcome? Drug Topics, v.144, n.14, p.43-50, 2000.
ORGANIZACIÓN MUNDIAL DE LA SALUD. El papel del 
Farmacéutico en la Atención a la Salud: Declaración de 
Tokio. Genebra: OMS, 1993. 37 p.
REDEKOP, W. K.; KOOPMANSCHAP, M. A.; STOLK, R. P.; 
RUTTEN, G. E.; WOLFFENBUTTELL, B. H.; NIESSEN, 
W. Health-related quality of life and treatment satisfaction 
in Dutch patients with type 2 diabetes. Diabetes Care, v.25, 
n.3, p.458-463. 2002.
SILVA CASTRO, M. M.; CALLEJA HERNANDEZ, M. A.; 
TUNEU, I.; VALLS, L.; FUENTES CAPARROS, B.; 
GUTIERREZ SAINZM, J.; FAUS DADER, J. Drug therapy 
follow-up in patients admitted to a Surgery Department. 
Farm. Hosp., v.28, n.3, p.154-169, 2004.
SOCIEDADE BRASILEIRA DE DIABETES. Atualização 
Brasileira sobre Diabetes 2006. Rio de Janeiro: Diographic, 
2005. 144 p.
SOCIEDADE BRASILEIRA DE DIABETES. Tratamento 
e acompanhamento do diabetes mellitus - Diretrizes 
da Sociedade Brasileira de Diabetes. Rio de Janeiro: 
Diagraphic, 2007. 168 p.
ZIMMET, P.; ALBERTI, K. G. M. M.; SHAW, J. Global and 
societal implications of the diabetes epidemic. Nature, 
v.414, n.6865, p.782-787, 2001. 
Received for publication on 12th November 2008.
Accepted for publication on 03rd March 2009. 

